| Literature DB >> 35722296 |
Julio Parra-Flores1, Ondřej Holý2, Sergio Acuña3, Sarah Lepuschitz4, Ariane Pietzka4, Alejandra Contreras-Fernández5, Pamela Chavarría-Sepulveda1, Ariadnna Cruz-Córdova6, Juan Xicohtencatl-Cortes6, Jetsi Mancilla-Rojano6,7, Alejandro Castillo8, Werner Ruppitsch4, Stephen Forsythe9.
Abstract
This study characterized five Cronobacter spp. and six Salmonella spp. strains that had been isolated from 155 samples of powdered infant formula (PIF) sold in Chile and manufactured in Chile and Mexico in 2018-2020. Two strains of Cronobacter sakazakii sequence type (ST) ST1 and ST31 (serotypes O:1 and O:2) and one strain of Cronobacter malonaticus ST60 (O:1) were identified. All Salmonella strains were identified as Salmonella Typhimurium ST19 (serotype O:4) by average nucleotide identity, ribosomal multilocus sequence typing (rMLST), and core genome MLST (cgMLST). The C. sakazakii and C. malonaticus isolates were resistant to cephalothin, whereas the Salmonella isolates were resistant to oxacillin and ampicillin. Nineteen antibiotic resistance genes were detected in the C. sakazakii and C. malonaticus isolates; the most prevalent were mcr-9.1, blaCSA , and blaCMA . In Salmonella, 30 genes encoding for aminoglycoside and cephalosporin resistance were identified, including aac(6')-Iaa, β-lactamases ampH, ampC1, and marA. In the Cronobacter isolates, 32 virulence-associated genes were detected by WGS and clustered as flagellar proteins, outer membrane proteins, chemotaxis, hemolysins, invasion, plasminogen activator, colonization, transcriptional regulator, survival in macrophages, use of sialic acid, and toxin-antitoxin genes. In the Salmonella strains, 120 virulence associated genes were detected, adherence, magnesium uptake, resistance to antimicrobial peptides, secretion system, stress protein, toxin, resistance to complement killing, and eight pathogenicity islands. The C. sakazakii and C. malonaticus strains harbored I-E and I-F CRISPR-Cas systems and carried Col(pHHAD28) and IncFIB(pCTU1) plasmids, respectively. The Salmonella strains harbored type I-E CRISPR-Cas systems and carried IncFII(S) plasmids. The presence of C. sakazakii and Salmonella in PIF is a health risk for infants aged less than 6 months. For this reason, sanitary practices should be reinforced for its production and retail surveillance.Entities:
Keywords: CRISPR-Cas; Cronobacter malonaticus; Cronobacter sakazakii; Salmonella Typhimurium; powdered infant formula; resistance genes; virulence; whole-genome sequencing
Year: 2022 PMID: 35722296 PMCID: PMC9201451 DOI: 10.3389/fmicb.2022.884721
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Identification of Cronobacter spp. and Salmonella spp. strains isolated from powdered infant formula by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) and whole-genome sequencing (WGS).
| Sample ID (MLST database) | Country | MALDI-TOF MS | WGS | ST | CC | Serotype |
|---|---|---|---|---|---|---|
| 510197-19 ( | Chile |
|
| 1 | 1 | O-1 |
| 510199-19 ( | Chile |
|
| 1 | 1 | O-1 |
| 510290-19 ( | Chile |
|
| 1 | 1 | O-1 |
| 510556-19 ( | Chile |
|
| 31 | 31 | O-2 |
| 510557-19 ( | Chile |
|
| 60 | 60 | O-1 |
| 510535-21 ( | Mexico | 19 | 19 | O-4:- | ||
| 510536-21 ( | Mexico | 19 | 19 | O-4:-:- | ||
| 510537-21 ( | Mexico | 19 | 19 | O-4:i:1,2 | ||
| 510538-21 ( | Mexico | 19 | 19 | O:4:i:1,2 | ||
| 510539-21 ( | Mexico | 19 | 19 |
| ||
| 510540-21 ( | Mexico | 19 | 19 |
|
ST, sequence type and CC, clonal complex.
MLST database ID.
cgMLST database ID. * Potential monophasic variant of S. Typhimurium.
Figure 1Minimum spanning tree (MST) of five strains of Cronobacter sakazakii and one of Cronobacter malonaticus from powdered infant formula manufactured in Chile, complemented with strains of C. sakazakii and C. malonaticus ST1, ST31, and ST60 of clinical and food origin. Calculation of the MST was based on the defined cgMLST scheme comprising 3,678 target genes for C. sakazakii and C. malonaticus. Isolates are represented as colored circles according to the classical MLST. Black numbers according to the allelic differences between isolates. Isolates with closely related genotypes are marked as Cluster.
Figure 2Minimum spanning tree of six Salmonella Typhimurium strains from powdered infant formula manufactured in Mexico and supplemented with other S. Typhimurium ST19 strains of clinical and food origin. Calculation of the MST was based on the defined cgMLST scheme comprising 3,002 target genes for Salmonella. Isolates are represented as colored circles according to the classical MLST. Black numbers according to the allelic differences between isolates. Isolates with closely related genotypes are marked as Cluster.
Antibiotic resistance profile of Cronobacter spp. and Salmonella spp. strains.
| Strain ID | Species | Antibiotics | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AM (10 μg) | AK (30 μg) | CL (30 μg) | CRO (30 μg) | CTX (30 μg) | FEP (30 μg) | GE (10 μg) | KF (30 μg) | LEV (5 μg) | NET (30 μg) | OX (1 μg) | SXT (25 μg) | |||
| 510197-19 |
|
| S | S | S | S | S | S |
| S | S | S | S | |
| 510199-19 |
| S | S | S | S | S | S | S |
| S | S | S | S | |
| 510290-19 |
| S |
| S | S | S | S | S |
| S | S | S | S | |
| 510556-19 |
| I |
| S | S | S | S | S |
| S | S | S | S | |
| 510557-19 |
|
| S | S | S | S | S | S |
| S | S | S | S | |
| 510535-21 | I | S | S | S | S | S | I | S | S | S |
| S | ||
| 510536-21 |
|
| S | S | I | S |
| S | S | S |
| S | ||
| 510537-21 |
| S | S | S | S | S | S |
| S | S |
| S | ||
| 510538-21 |
| S | S | S | S | S | S |
| S | S |
| S | ||
| 510539-21 |
| S | S | S | S | S | S |
| S | S |
| S | ||
| 510540-21 |
| S | S | S | S | S | S |
| S | S |
| S | ||
AM, ampicillin; AK, amikacin; CL, chloramphenicol; CRO, ceftriaxone; CTX, cefotaxime; FEP, cefepime; GE, gentamicin; KF, cephalothin; LEV, levofloxacin; NET, netilmicin; OX, oxacillin; SXT, trimethoprim/sulfamethoxazole; R, resistance; and S, susceptibility; I, intermediate. The values in parentheses in bold correspond to the concentrations of antibiotics.
Antibiotic-resistant genes of Cronobacter spp. strains identified by Comprehensive Antibiotic Resistance Database (CARD).
| Best hits antibiotic resistance ontology (ARO) | Drug class | Resistance mechanism | 510197-19 (ST1) | 510199-19 (ST1) | 510290-18 (ST1) | 510556-19 (ST31) | 510557-19 (ST60) |
|---|---|---|---|---|---|---|---|
|
| Peptide antibiotic | Antibiotic target alteration | + | + | + | − | − |
|
| Cephalosporin | Antibiotic inactivation | + | + | + | + | − |
|
| Cephalosporin | Antibiotic inactivation | − | − | − | − | + |
|
| Cephalosporin, cephamycin, and penam | Antibiotic target alteration | + | + | + | + | + |
|
| Fosfomycin | Antibiotic target alteration | + | + | + | + | + |
|
| Elfamycin antibiotic | Antibiotic target alteration | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, triclosan, rifamycin antibiotic, penam, phenicol antibiotic, glycylcycline, tetracycline antibiotic, and cephalosporin | Antibiotic target alteration | + | + | + | + | + |
|
| Fluoroquinolone antibiotic and tetracycline antibiotic | Antibiotic efflux | + | + | + | + | + |
|
| Macrolide antibiotic, fluoroquinolone antibiotic, cephalosporin, cephamycin, penam, and tetracycline antibiotic | Antibiotic efflux | + | + | + | + | + |
|
| Nitroimidazole antibiotic | Antibiotic efflux | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, monobactam, carbapenem, cephalosporin, glycylcycline, cephamycin, penam, tetracycline antibiotic, rifamycin antibiotic, phenicol antibiotic, triclosan, and penem | Antibiotic efflux | + | + | + | + | + |
|
| Macrolide antibiotic, aminoglycoside antibiotic, cephalosporin, tetracycline antibiotic, peptide antibiotic, and rifamycin antibiotic | Antibiotic efflux | + | + | + | + | + |
|
| Macrolide antibiotic, aminoglycoside antibiotic, cephalosporin, tetracycline antibiotic, peptide antibiotic, and rifamycin antibiotic | Antibiotic efflux | + | + | + | + | + |
|
| Fluoroquinolone antibiotic | Antibiotic efflux | + | + | + | + | + |
|
| Fluoroquinolone antibiotic | Antibiotic efflux | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, diaminopyrimidine antibiotic, and phenicol antibiotic | Antibiotic efflux | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, macrolide antibiotic, and penam | Antibiotic efflux | + | + | + | + | + |
|
| Macrolide antibiotic, fluoroquinolone antibiotic, aminoglycoside antibiotic, carbapenem, cephalosporin, penam, peptide antibiotic, and penem | Antibiotic efflux | − | − | − | − | − |
| Cephalosporin and penam | Antibiotic inactivation | + | + | + | + | + |
+, presence and −, absence.
Antibiotic-resistant genes of S. Typhimurium strains identified by CARD.
| Best hits antibiotic resistance ontology (ARO) | Drug class | Resistance mechanism | 510535-21 | 510536-21 | 510537-21 | 510538-21 | 510539-21 | 510540-21 |
|---|---|---|---|---|---|---|---|---|
|
| Aminoglycoside antibiotic | Antibiotic inactivation | + | + | + | + | + | + |
| Cephalosporin and penam | Antibiotic inactivation | + | + | + | + | + | + | |
| Cephalosporin and penam | Antibiotic inactivation | + | + | + | + | + | + | |
|
| Peptide antibiotic | Antibiotic target alteration | + | + | + | + | + | + |
|
| Peptide antibiotic | Antibiotic target alteration | + | + | + | + | + | + |
|
| Fosfomycin | Antibiotic target alteration | + | + | + | + | + | + |
|
| Fosfomycin | Antibiotic target alteration | + | + | + | + | + | + |
|
| Cephalosporin, cephamycin, and penam | Antibiotic target alteration | + | + | + | + | + | + |
|
| Elfamycin antibiotic | Antibiotic target alteration, antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, monobactam, carbapenem, cephalosporin, glycylcycline, cephamycin, penam, tetracycline antibiotic, rifamycin antibiotic, phenicol antibiotic, triclosan, and penem | Antibiotic target alteration, antibiotic efflux, reduced permeability to antibiotic | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, cephalosporin, glycylcycline, penam, tetracycline antibiotic, rifamycin antibiotic, phenicol antibiotic, and triclosan | Antibiotic target alteration, antibiotic efflux, and reduced permeability to antibiotic | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, cephalosporin, glycylcycline, penam, tetracycline antibiotic, rifamycin antibiotic, phenicol antibiotic, and triclosan | Antibiotic target alteration, antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, cephalosporin, glycylcycline, penam, tetracycline antibiotic, rifamycin antibiotic, phenicol antibiotic, and triclosan | Antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, cephalosporin, glycylcycline, penam, tetracycline antibiotic, rifamycin antibiotic, phenicol antibiotic, and triclosan | Antibiotic efflux | + | + | + | + | + | + |
|
| Monobactam, carbapenem, cephalosporin, cephamycin, penam, phenicol antibiotic, and penem | Antibiotic efflux | + | + | + | + | + | + |
|
| Monobactam, carbapenem, cephalosporin, cephamycin, penam, phenicol antibiotic, and penem | Antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, and tetracycline antibiotic | Antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, monobactam, carbapenem, cephalosporin, glycylcycline, cephamycin, penam, tetracycline antibiotic, rifamycin antibiotic, phenicol antibiotic, triclosan, and penem | Antibiotic efflux, reduced permeability to antibiotic | + | + | + | + | + | + |
|
| Macrolide antibiotic, aminoglycoside antibiotic, cephalosporin, tetracycline antibiotic, peptide antibiotic, and rifamycin antibiotic | Antibiotic efflux | + | + | + | + | + | + |
|
| Macrolide antibiotic, aminoglycoside antibiotic, cephalosporin, tetracycline antibiotic, peptide antibiotic, and rifamycin antibiotic | Antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic | Antibiotic efflux | + | − | + | + | + | + |
|
| Fluoroquinolone antibiotic | Antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, diaminopyrimidine antibiotic, and phenicol antibiotic | Antibiotic efflux | + | + | + | + | + | + |
|
| Aminoglycoside antibiotic and aminocoumarin antibiotic | Antibiotic efflux | + | + | + | + | + | + |
|
| Macrolide antibiotic, fluoroquinolone antibiotic, cephalosporin, cephamycin, penam, and tetracycline antibiotic | Antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, cephalosporin, glycylcycline, penam, tetracycline antibiotic, rifamycin antibiotic, phenicol antibiotic, and triclosan | Antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic, macrolide antibiotic, and penam | Antibiotic efflux | + | + | + | + | + | + |
|
| Fluoroquinolone antibiotic | Antibiotic efflux | + | + | + | + | + | + |
|
| Macrolide antibiotic, fluoroquinolone antibiotic, and penam | Antibiotic efflux | − | + | + | + | + | + |
|
| Aminoglycoside antibiotic | Antibiotic efflux | + | + | + | + | + | + |
+, presence and −, absence.
Putative virulence and distribution of other genes in seven strains of Cronobacter spp. by WGS.
| Virulence gene | Function | 510197-19 (ST1) | 510199-19 (ST1) | 510290-18 (ST1) | 510556-19 (ST31) | 510557-19 (ST60) | ES15 control (ST125) | ||
|---|---|---|---|---|---|---|---|---|---|
|
| Motility | + | + | + | + | + | + | + | + |
|
| Flagellar hook-associated protein 1 | + | + | + | + | + | + | + | + |
|
| Flagellar hook-associated protein 3 | + | + | + | + | + | + | + | − |
|
| Negative regulator of flagellin synthesis | + | + | + | + | + | + | + | + |
|
| Flagellar synthesis FlgN protein | + | + | + | + | + | + | + | + |
|
| Flagellar hook-associated protein 2 | + | + | + | + | + | + | + | + |
|
| Flagellar operon FliA | + | + | + | + | + | + | + | + |
|
| Flagellin | + | + | + | + | + | − | + | − |
|
| Flagellar hook-associated protein 2 | + | + | + | + | + | + | + | + |
|
| Flagellar biosynthetic FliR protein | + | + | + | + | + | + | + | + |
|
| Flagellar FliT protein | + | + | + | + | + | + | + | + |
|
| FliZ protein | + | + | + | + | + | + | + | + |
|
| Outer membrane lipoprotein carrier protein | + | + | + | + | + | + | + | + |
|
| Chemotaxis MotA protein | + | + | + | + | + | + | + | + |
|
| LuxR family transcriptional regulator | + | + | + | + | + | + | + | + |
|
| Outer membrane lipoprotein SlyB | + | + | + | + | + | + | + | + |
|
| Outer membrane channel protein | + | + | + | + | + | + | + | + |
|
| Survival in macrophage | + | + | + | + | + | + | − | + |
|
| Protective immunity and colonization | + | + | + | + | + | + | + | + |
|
| Plasminogen activator | + | + | + | + | − | + | − | − |
|
| Hemolysin | + | + | + | + | + | + | − | + |
|
| Adhesion cell, biofilm formation | + | + | + | + | + | + | + | + |
|
| Adhesion cell | + | + | + | + | + | + | + | + |
|
| Chemotaxis protein methyltransferase | + | + | − | + | + | − | + | − |
|
| Response regulator of chemotaxis family | + | + | + | + | + | + | + | + |
|
| Desiccation tolerance | + | + | + | + | + | + | + | + |
|
| Epithelial cell invasion and lipid A production | + | + | + | + | + | + | + | + |
|
| Exogenous sialic acid utilization | + | + | + | + | − | + | − | + |
|
| Small heat shock protein | + | + | + | + | + | + | + | + |
|
| Desiccation tolerance | + | + | + | + | + | + | + | + |
|
| Cell filamentation protein | + | + | + | + | + | + | + | + |
|
| RelE antitoxin | + | + | + | + | + | + | − | + |
+, presence and −, absence.
Putative virulence and distribution of other genes in six strains of S. Typhimurium by WGS.
| Genes | 510535 | 510536 | 510537 | 510538 | 510539 | 510540 | |
|---|---|---|---|---|---|---|---|
|
|
| + | + | + | + | + | + |
|
| + | − | + | + | + | + | |
|
| + | − | − | + | − | − | |
|
| + | − | − | + | + | + | |
|
| + | − | + | + | − | + | |
|
| + | + | + | + | + | + | |
|
|
| + | + | + | + | + | + |
|
| + | + | + | + | + | + | |
|
| + | + | + | + | + | + | |
|
| + | + | − | + | + | − | |
|
| + | + | + | + | + | + | |
|
| + | + | + | + | + | + | |
|
| + | + | + | + | + | + | |
|
| + | + | + | + | + | + |
+, presence and −, absence.
Plasmids and mobile genetic elements of Cronobacter spp. and S. Typhimurium.
| Bacteria | ID strain | Plasmid | Plasmids accession number | Mobile genetic elements |
|---|---|---|---|---|
|
| 510197-19 | Col(pHDA28) | KU674895 | IS903, IS26, ISEsa2, IS5075, ISEsa1, ISPpu12, IS102 |
| 510199-19 | Col(pHDA28) | KU674895 | IS903, IS26. ISEsa2, IS5075, ISEsa1, ISPpu12, IS102 | |
| 510290-18 | Col(pHDA28) | KU674895 | ISEsa2, IS5075, ISEsa1, ISPpu12, IS102 | |
| 510556 | ---- | ISEsa1 | ||
|
| 510557-19 | IncFIB(pCTU1) | FN543094 | IS481 |
| 510535-21 | IncFII(S) | FN543094 | ISSen7, ISSty2,ISEcI10, MITEEcl, ISSen1 | |
| 510536-21 | IncFIB(S) | FN432031 | ISSen7, ISSen1, MITEEc1, ISEcl10 | |
| 510537-21 | IncFII(S) | FN543094 | ISSen7, MITEEcl, ISSen1, ISEcI10, ISSty2 | |
| 510538-21 | IncFII(S) | FN543094 | ISSen7, MITEEcl, ISEcI10, ISSen1 | |
| 510539-21 | IncFII(S) | FN543094 | ISSen7, MITEEcl, ISSen1, ISSty2, ISEcI10 | |
| 510540-21 | IncFII(S) | FN543094 | ISSen7, MITEEcl, ISSen1, ISEcI10 |
CRISPR-Cas systems identified in the Cronobacter spp. and Salmonella spp. genomes.
| Strains | Operon structure type | Position | Maximum number of spacers per strain | Number of CRISPR arrays per strain | Repeat consensus | |
|---|---|---|---|---|---|---|
| 510197- | Type I-F CAS | 77362-76641 | 12 | 13 | GTTCACTGCCGTACAGGCAGCTTAGAAA | DEDDh |
| Type I-E CAS | 171199-172847 | 27 | 28 | CTGTTCCCCGCGCGAGCGGGGATAAACCG | ||
| 199092-200862 | 29 | 30 | GTGTTCCCCGCGCGAGCGGGGATAAACCG | |||
| 510199- | Type I-E CAS | 482009-482670 | 11 | 12 | GTTCACTGCCGTACAGGCAGCTTAGAAA | |
| 77461-79109 | 27 | 28 | CGGTTTATCCCCGCTCGCGCGGGGAA | |||
| 105476-107002 | 25 | 26 | CGGTTTATCCCCGCTCGCGCGGGGAACAG | |||
| 510290- | Type I-F CAS | 480714-481435 | 12 | 13 | GTTCACTGCCGTACAGGCAGCTTAGAAA | DEDDh, |
| -Type I-E CAS | 173384-175032 | 27 | 28 | CTGTTCCCCGCGCGAGCGGGGATAAACCG | ||
| 201277-203047 | 29 | 30 | GTGTTCCCCGCGCGAGCGGGGATAAACCG | |||
| 510556- | Type I-F CAS | 161191-162091 | 9 | 10 | CTGTTCCCCGCGCGAGCGGGGATAAACCG | |
| -Type I-E CAS | 7728-8277 | 15 | 16 | GTGTTCCCCGCGCGAGCGGGGATAAACCG | ||
| 199129-200044 | 15 | 16 | GTTCACTGCCGTACAGGCAGCTTAGAAA | |||
| 510557- | -Type I-E CAS | 6074-7051 | 17 | 18 | GTGTTCCCCGCGCGAGCGGGGATAAACCG | |
| 165212-166676 | 25 | 26 | CTGTTCCCCGCGCGAGCGGGGATAAACCG | |||
| 510535- | Type I-E CAS | 241410-242857 | 24 | 25 | GTGTTCCCCGCGCCAGCGGGGATAAACCG |
|
| 259017-260604 | ||||||
| 27 | 28 | GTGTTCCCCGCGCCAGCGGGGATAAACCG | ||||
| 510536- | Type I-E CAS | 7220-8807 | 27 | 28 | GTGTTCCCCGCGCCAGCGGGGATAAACCG |
|
| 27933-29380 | 24 | 25 | GTGTTCCCCGCGCCAGCGGGGATAAACCG | |||
| 510537- | Type I-E CAS | 5320-6907 | 27 | 28 | GTGTTCCCCGCGCCAGCGGGGATAAACCG |
|
| 23067-24514 | 24 | 25 | GTGTTCCCCGCGCCAGCGGGGATAAACCG | |||
| 510538- | Type I-E CAS | 166775-165328 | 24 | 25 | GTGTTCCCCGCGCCAGCGGGGATAAACCG |
|
| 184522-182935 | 27 | 28 | GTGTTCCCCGCGCCAGCGGGGATAAACCG | |||
| 510539- | Type I-E CAS | 5479-7066 | 24 | 25 | GTGTTCCCCGCGCCAGCGGGGATAAACCG |
|
| 8963-10410 | 27 | 28 | GTGTTCCCCGCGCCAGCGGGGATAAACCG | |||
| 510540- | -Type I-E CAS | 161008-162455 | 24 | 25 | GTGTTCCCCGCGCCAGCGGGGATAAACCG |
|
| 178615-180202 | 27 | 28 | GTGTTCCCCGCGCCAGCGGGGATAAACCG |
Characteristic repeated sequences of the identified CRISPR arrays and their position in the genome.
Figure 3CRISPR-Cas systems identified in Cronobacter spp. and Salmonella spp. genomes. The identified systems belong to the I-E and I-F CRISPR-Cas systems.